Tinea Pedis Clinical Trial
Official title:
Non-inferiority, Phase III Clinical Trial Comparing Dapaconazole Cream 2% (Biolab Sanus Farmacêutica Ltda.) Versus Ketoconazole Cream 2% (Nizoral® Janssen-Cilag) in Patients With Tinea Pedis
This is a non-inferiority, Phase III, open-label, randomized, parallel trial to evaluate the
new intervention Dapaconazole cream 2% versus Ketoconazole cream 2% in patients with Tinea
pedis. Sample size is 140 participants (70 per treatment group), male or female, aged
between 16 and 60 years-old.
Primary objective is to evaluate non-inferiority of Dapaconazole cream 2% compared to
Ketoconazole cream 2% in Tinea pedis treatment. Secondary objective is to evaluate safety
and tolerability of Dapaconazole cream 2% after multiple administrations.
Participants will receive either new intervention or active control during 14 consecutive
days, which will be followed by 2 follow-up visits.
Primary efficacy endpoint is clinical and mycological lesion cure, and secondary efficacy
endpoint is time (days) until clinical diagnosis of lesion cure. Additionally, safety will
be assessed by adverse events occurrence and laboratory exams evaluation.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05493488 -
A Trial to Evaluate the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With Tinea Pedis
|
Phase 2 | |
Completed |
NCT04883593 -
A Study Comparing the Efficacy of TA103 and the Placebo Control in the Treatment of Interdigital Tinea Pedis.
|
Early Phase 1 | |
Terminated |
NCT02842021 -
Efficacy and Safety of Product S2G6T-1in Patients With Symptomatic Inflammatory Interdigital Tinea Pedis
|
Phase 2 | |
Completed |
NCT01712360 -
Pharmacokinetic Study of Pediatric Subjects With Tinea Cruris and Tinea Pedis
|
Phase 4 | |
Completed |
NCT00781664 -
Cumulative Irritation Test
|
Phase 1 | |
Completed |
NCT03676686 -
Study With Nåva Foot Cream in Patients With Tinea Pedis Interdigitalis
|
N/A | |
Completed |
NCT01519752 -
A Therapeutic Equivalence Study of Two Oxiconazole Nitrate Topical Cream Treatments for Patients With Tinea Pedis
|
Phase 1 | |
Completed |
NCT03320486 -
Non-inferiority Trial of Dapaconazole Versus Ketoconazole
|
Phase 3 | |
Completed |
NCT01580891 -
Evaluate the Clinical Equivalence of Two Naftifine HCl 1% Creams in Patients With Interdigital Tinea Pedis
|
Phase 1 | |
Completed |
NCT01353976 -
Safety and Efficacy of Econazole Nitrate Foam 1% in Subjects With Tinea Pedis
|
Phase 3 | |
Completed |
NCT01349998 -
Safety of a Topical Antifungal Treatment for Tinea Cruris, Tinea Pedis and Tinea Corporis
|
Phase 3 | |
Completed |
NCT04265521 -
Study With BioCool Footcare in Subjects With Tinea Pedis Interdigitalis and Heel Cracks, Calluses and/or Dry Feet
|
N/A | |
Completed |
NCT02633813 -
BE Study of Naftifine HCL
|
Phase 3 | |
Recruiting |
NCT00856596 -
Once a Day Topical Treatment for Athlete's Foot Fungus Inbetween the Toes in Males and Females
|
Phase 3 | |
Completed |
NCT00869336 -
Multicenter Study of the Efficacy and Safety of Luliconazole Cream in Tinea Pedis (Athlete's Foot)
|
Phase 2 | |
Completed |
NCT00768599 -
A Study of Econazole Foam 1% in Athlete's Foot
|
Phase 2 | |
Recruiting |
NCT00233493 -
Spread of Dermatophytes Among Families
|
N/A | |
Completed |
NCT03897257 -
A Comparison Study of UHE-103 Cream in Subjects With Moccasin Type Tinea Pedis
|
Phase 2 | |
Completed |
NCT03129321 -
Therapeutic Equivalence and Safety of Two Econazole Nitrate Cream, 1% Products in Tinea Pedis
|
Phase 3 | |
Completed |
NCT02335255 -
Evaluate Safety and Efficacy of Naftifine Hydrochloride Gel 2% and Naftin® Gel 2% in Tinea Pedis
|
Phase 1 |